JS Torgerson, J Hauptman, MN Boldrin, L Sjöström - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Of orlistat-treated patients, 52% completed treatment compared with 34% of placebo
recipients (P < 0.0001). After 4 years' treatment, the cumulative incidence of diabetes was
9.0% with placebo and 6.2% with orlistat, corresponding to a risk reduction of 37.3% (P = ... Cited by 737 - Related articles - BL Direct - All 10 versions
JL Chiasson, RG Josse, R Gomis, M Hanefeld, A … - The Lancet, 2002 - Elsevier We randomly allocated 714 patients with impaired glucose tolerance to acarbose and 715 to
placebo. We excluded 61 (4%) patients because they did not have impaired glucose tolerance
or had no postrandomisation data. 211 (31%) of 682 patients in the acarbose group and ... Cited by 1218 - Related articles - All 14 versions
- ►lindaxa.cz [PDF] WPT James, A Astrup, N Finer, J Hilsted, P Kopelman, … - The Lancet, 2000 - Elsevier Eight European centres recruited 605 obese patients (body-mass index 30-45 kg/m 2 ) for a
6-month period of weight loss with sibutramine (10 mg/day) and an individualised 600 kcal/day
deficit programme based on measured resting metabolic rates. 467 (77%) patients with ... Cited by 656 - Related articles - BL Direct - All 10 versions
- ►diabetesjournals.org TA Buchanan, AH Xiang, RK Peters, SL Kjos, A … - Diabetes, 2002 - Am Diabetes Assoc Type 2 diabetes frequently results from progressive failure of pancreatic β-cell function in the
presence of chronic insulin resistance. We tested whether chronic amelioration of insulin resistance
would preserve pancreatic β-cell function and delay or prevent the onset of type 2 ... Cited by 926 - Related articles - BL Direct - All 6 versions
DE Kelley, GA Bray, FX Pi-Sunyer, S Klein, J Hill, J … - Diabetes Care, 2002 - Am Diabetes Assoc OBJECTIVE—Weight loss improves glycemic control, lipid profiles, and blood pressure in patients
with type 2 diabetes. However, successful long-term weight loss is difficult for these patients,
particularly those treated with insulin. The aim of this study was to assess the effect of ... Cited by 174 - Related articles - BL Direct - All 7 versions
JM Miles, L Leiter, P Hollander, T Wadden, JW … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—After 1 year of treatment, mean (±SE) weight loss was greater in the orlistat than
in the placebo group (−4.6 ± 0.3% vs. −1.7 ± 0.3% of baseline wt, P < 0.001). Orlistat treatment
caused a greater improvement in glycemic control than placebo, as evidenced by a ... Cited by 172 - Related articles - BL Direct - All 7 versions
R Padwal, SK Li, DCW Lau - International journal of obesity, 2003 - nature.com CONTEXT: Safe and effective strategies to curb rising obesity prevalence rates are urgently needed
and medications may play a more prominent role in future therapeutic regimens. ...
OBJECTIVE: To review systematically the long-term efficacy and safety of approved ... Cited by 317 - Related articles - BL Direct - All 10 versions
MH Davidson, J Hauptman, M DiGirolamo, JP Foreyt, … - Jama, 1999 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do to make
your experience on this site better. ... Add to CiteULike Add to Connotea Add to ... Cited by 644 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org [PDF] PA Hollander, SC Elbein, IB Hirsch, D Kelley, J … - Diabetes care, 1998 - Am Diabetes Assoc Obesity is a significant cause of type 2 diabetes (1,2). It is also the most impo rtant modifiable
factor for this disease in both men and women (3). The incidence of type 2 diabetes rises with
inc reasing severity of obesity, and also with weight gain per se, independent of baseline ... Cited by 545 - Related articles - BL Direct - All 6 versions
Z Li, M Maglione, W Tu, W Mojica, D … - Annals of internal …, 2005 - Am Coll Physicians Background: In response to the increase in obesity, pharmacologic treatments for weight loss
have become more numerous and more commonly used. ... Purpose: To assess the efficacy
and safety of weight loss medications approved by the US Food and Drug Administration ... Cited by 327 - Related articles - BL Direct - All 8 versions
